Hamps Bio shares for the first time at a premium of 90% on the BSE SME platform
Hamps Bio Ltd shares made a positive debut on the BSE SME platform on 20 December 2024, trading at Rs 96.9, a premium of 90 per cent over its issue price of Rs 51. Initial Public Offering (IPO), new stock market. , received an amazing response and was oversubscribed 1000 times.
Use of IPO funds
Hamps Bio intends to use the Rs 10.71 crore raised through its IPO to buy equipment for its FMCG division, strengthen brand visibility, and carry out other corporate objectives.
Expanding product portfolio and market presence
Hamps Bio is a recognized player in the marketing and production of ethical medicine. Its portfolio includes more than 180 pharmaceutical formulations such as tablets, syrups, tablets, injections, and nutritional products, as well as frozen food and ice products under its brand ‘FzyEzy.’ The company’s pharmaceutical products are distributed in eight Indian states and union territories, while its FDFP products are exported to six countries.
Financial summary
For the period ending October 2024, the company reported revenue of Rs 4.36 crore and net profit of Rs 34 lakh.
India’s important role in world pharmacy
The growth of Hamps Bio is in line with India’s important role in the global pharmaceutical space. The country accounts for 20 percent of the global supply of generic drugs and 60 percent of vaccine supply, highlighting strong opportunities for domestic players such as Hamps Bio.
With its strong start, Hamps Bio reinforces investor confidence in India’s growing SME segment, particularly in pharmaceuticals and FMCG, demonstrating its long-term growth potential.
